Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyams

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Translational Medicine|November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaOmid Hamid, Henrik Schmidt, Aviram Nissan, et al.
The American Journal of Managed Care|July 9, 2020
A path to improve colorectal cancer screening outcomes: faculty roundtable evaluation of cost-effectiveness and utilityRichard H Bone, James D Cross, Andrea J Dwyer, et al.
Journal of Surgical Oncology|February 18, 2017
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assaysDavid M Hyams, Eric Schuur, Javier Angel Aristizabal, et al.
Investigational New Drugs|June 27, 2013
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II studyDavid M Hyams, Arlene Chan, Celia de Oliveira, et al.
Journal of Surgical Oncology|June 27, 2024
Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assaysDavid M Hyams, Avital Bareket-Samish, Juan Enrique Bargallo Rocha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulatorCarol J Fabian, Bruce F Kimler, Julie Anderson, et al.
JCO Precision Oncology|September 27, 2021
Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis PredictionEric D Whitman, Vadim P Koshenkov, Brian R Gastman, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Translational Medicine|November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaOmid Hamid, Henrik Schmidt, Aviram Nissan, et al.
The American Journal of Managed Care|July 9, 2020
A path to improve colorectal cancer screening outcomes: faculty roundtable evaluation of cost-effectiveness and utilityRichard H Bone, James D Cross, Andrea J Dwyer, et al.
Journal of Surgical Oncology|February 18, 2017
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assaysDavid M Hyams, Eric Schuur, Javier Angel Aristizabal, et al.
Investigational New Drugs|June 27, 2013
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II studyDavid M Hyams, Arlene Chan, Celia de Oliveira, et al.
Journal of Surgical Oncology|June 27, 2024
Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assaysDavid M Hyams, Avital Bareket-Samish, Juan Enrique Bargallo Rocha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulatorCarol J Fabian, Bruce F Kimler, Julie Anderson, et al.
JCO Precision Oncology|September 27, 2021
Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis PredictionEric D Whitman, Vadim P Koshenkov, Brian R Gastman, et al.
Pageof 2